5 October 2021 - - US-based T Cell Receptor Therapy (TCR-T) products developer T-Cure Bioscience, Inc and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies for oncology targets, have inked a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb, the companies said.

These will be used to develop a diagnostic test to identify tumors that express KK-LC-1. Patients with KK-LC-1 positive tumors may be eligible for inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.

Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development.

T-Cure is developing TCR-T therapeutics targeting Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) for gastric, triple negative breast cancer, cervical, lung and other KK-LC-1 positive cancers.

T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsored clinical trial planned for 2022.

T-Cure Bioscience is an immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer.

The company focuses on developing high avidity TCR that can be used to engineer a patient's T cells to effectively target and destroy solid tumors.

The company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1 novel antigens associated with solid tumors with significant unmet medical needs, including kidney cancer, triple negative breast cancer, lung cancer, gastric cancer and others.

Atlas Antibodies AB was founded in 2006 as a start-up from the Human Protein Atlas project and has over the last 15 years successfully launched more than 60,000 products for protein research.

The company was founded by researchers at the Royal Institute of Technology in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala to handle the production, marketing and sales of research tools developed by the Swedish-based Human Protein Atlas program.

Headquartered in Stockholm, Sweden, Atlas Antibodies provides high-quality reagents for biomedical research, including polyclonal and monoclonal antibodies and QPrESTs.

Earlier this year, Atlas Antibodies acquired UK-based HistoCyte Laboratories a leading supplier of cell line controls for pathology applications, and Swiss-based Evitria an expert provider of antibody expression services.